Modeling of corneal and retinal pharmacokinetics after periocular drug administration

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 1, 2008, Pages 320-332

  Amrite, Aniruddha C ^a,d   Edelhauser, Henry F ^c   Kompella, Uday B ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c EMORY EYE CENTER   (United States)

^d IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; PREDNISOLONE; CYCLOOXYGENASE 2 INHIBITOR; GLUCOCORTICOID; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BROWN NORWAY RAT; CHOROID; CONTROLLED STUDY; CORNEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG RELEASE; DRUG SOLUBILITY; EXPERIMENTAL RABBIT; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RAT; RETINA; SPRAGUE DAWLEY RAT; SUSTAINED RELEASE FORMULATION; ANIMAL; BIOLOGICAL MODEL; CONJUNCTIVA; DRUG EFFECT; METABOLISM; PERMEABILITY; RABBIT; VALIDATION STUDY;

ANIMALS; CONJUNCTIVA; CORNEA; CYCLOOXYGENASE 2 INHIBITORS; GLUCOCORTICOIDS; MODELS, BIOLOGICAL; PERMEABILITY; PREDNISOLONE; PYRAZOLES; RABBITS; RATS; RATS, INBRED BN; RATS, SPRAGUE-DAWLEY; RETINA; SULFONAMIDES; VALIDATION STUDIES AS TOPIC;

EID: 38749087775     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.07-0593     Document Type: Article

References (60)

1. Maurice DM. Drug delivery to the posterior segment from drops. Surv Ophthalmol. 2002;47(suppl 1):S41-S52.
2. Raghava S, Hammond M, Kompella UB. Periocular routes for retinal drug delivery. Expert Opin Drug Deliv. 2004;1:99-114.
3. Ranta VP, Urtti A. Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling. Adv Drug Deliv Rev. 2006;58:1164-1181.
4. Tsuji A, Tamai I, Sasaki K. Intraocular penetration kinetics of prednisolone after subconjunctival injection in rabbits. Ophthalmic Res. 1988;20:31-43.
5. Lee TW, Robinson JR. Drug delivery to the posterior segment of the eye II: development and validation of a simple pharmacokinetic model for subconjunctival injection. J Ocul Pharmacol Ther. 2004;20:43-53.
6. Weijtens O, Feron EJ, Schoemaker RC, et al. High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. Am J Ophthalmol. 1999;128:192-197.
7. Rootman J, Ostry A, Gudauskas G. Pharmacokinetics and metabolism of 5-fluorouracil following subconjunctival versus intravenous administration. Can J Ophthalmol. 1984;19:187-191.
8. Souli M, Kopsinis G, Kavouklis E, Gabriel L, Giamarellou H. Vancomycin levels in human aqueous humour after intravenous and subconjunctival administration. Int J Antimicrob Agents. 2001;18:239-243.
9. Rowland M, Balant L, Peck C. Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report. Georgetown University, Washington, DC, May 29-30, 2002. AAPS PharmSci. 2004;6:E6.
10. Loizou GD, Spendiff M. A human PBPK model for ethanol describing inhibition of gastric motility. J Mol Histol. 2004;35:687-696.
11. Cheruvu NP, Amrite AC, Kompella UB. Effect of eye pigmentation on trans-scleral drug delivery. Invest Ophthalmol Vis Sci. In press.
12. Ayalasomayajula SP, Kompella UB. Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. Pharm Res. 2004;21:1797-1804.
13. Li SK, Molokhia SA, Jeong EK. Assessment of subconjunctival delivery with model ionic permeants and magnetic resonance imaging. Pharm Res. 2004;21:2175-2184.
14. Robinson MR, Lee SS, Kim H, et al. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp Eye Res. 2006;82:479-487.
15. Kim SH, Galban CJ, Lutz RJ, et al. Assessment of subconjunctival and intrascleral drug delivery to the posterior segment using dynamic contrast-enhanced magnetic resonance imaging. Invest Ophthalmol Vis Sci. 2007;48:808-814.
16. Makoid MC, Robinson JR. Pharmacokinetics of topically applied pilocarpine in the albino rabbit eye. J Pharm Sci. 1979;68:435-443.
17. Maurice DM, Mishima S. Ocular pharmacokintics. In: Sears ML, ed. Pharmacology of the Eye. New York: Springer; 1984:19-116.
18. Sasaki H, Kashiwagi S, Mukai T, et al. Topical delivery system of ophthalmic drugs by periocular injection with viscous solution. Biol Pharm Bull. 1999;22:961-965.
19. Sasaki H, Kashiwagi S, Mukai T, et al. Drug absorption behavior after periocular injections. Biol Pharm Bull. 1999;22:956-960.
20. Wine NA, Gornall AG, Basu PK. The ocular uptake of subconjunctivally injected 14C-hydrocortisone. Am J Ophthalmol. 1964;58:362-366.
21. Kim H, Csaky KG, Gilger BC, et al. Preclinical evaluation of a novel episcleral cyclosporine implant for ocular graft-versus-host disease. Invest Ophthalmol Vis Sci. 2005;46:655-662.
22. Lee SS, Kim H, Wang NS, et al. A pharmacokinetic and safety evaluation of an episcleral cyclosporine implant for potential use in high-risk keratoplasty rejection. Invest Ophthalmol Vis Sci. 2007;48:2023-2029.
23. Levy JH. Intraocular sporotrichosis. Report of a case. Arch Ophthalmol. 1971;85:574-579.
24. Smolen VF, Siegel FP. Procaine interaction with the corneal surface and its relation to anesthesia. J Pharm Sci. 1967;57:378-384.
25. Polse KA, Keener RJ, Jauregui MJ. Dose-response effects of corneal anesthetics. Am J Optom Physiol Opt. 1978;55:8-14.
26. Hoffmann F, Zhang EP, Mueller A, et al. Contribution of lymphatic drainage system in corneal allograft rejection in mice. Graefes Arch Clin Exp Ophthalmol. 2001;239:850-858.
27. Bonate PL. The Art of Modeling: Pharmacokinetic-Pharmacodynamic Modeling and Simulation. New York: Springer Science and Business Media Inc; 2006:1-56.
28. Zhao L, Orton E, Vemuri NM. Predicting solubility in multiple nonpolar drugs-cyclodextrin system. J Pharm Sci. 2002;91:2301-2306.
29. Garti N, Avrahami M, Aserin A. Improved solubilization of Celecoxib in U-type nonionic microemulsions and their structural transitions with progressive aqueous dilution. J Colloid Interface Sci. 2006;299:352-365.
30. Seedher N, Bhatia S. Solubility enhancement of Cox-2 inhibitors using various solvent systems. AAPS PharmSciTech. 2003;4:E33.
31. Dahlin DC, Rahimy MH. Pharmacokinetics and metabolism of anecortave acetate in animals and humans. Surv Ophthalmol. 2007;52(suppl 1):S49-S61.
32. Kaiser PK, Goldberg MF, Davis AA. Posterior juxtascleral depot administration of anecortave acetate. Surv Ophthalmol. 2007;52(suppl 1):S62-S69.
33. Saishin Y, Silva RL, Saishin Y, et al. Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model. Invest Ophthalmol Vis Sci. 2003;44:4989-4993.
34. Okabe K, Kimura H, Okabe J, et al. Effect of benzalkonium chloride on transscleral drug delivery. Invest Ophthalmol Vis Sci. 2005;46:703-708.
35. Hayden BC, Jockovich ME, Murray TG, et al. Pharmacokinetics of systemic versus focal Carboplatin chemotherapy in the rabbit eye: possible implication in the treatment of retinoblastoma. Invest Ophthalmol Vis Sci. 2004;45:3644-3649.
36. Amrite AC, Ayalasomayajula SP, Cheruvu NP, Kompella UB. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest Ophthalmol Vis Sci. 2006;47:1149-1160.
37. Ayalasomayajula SP, Kompella UB. Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Eur J Pharmacol. 2005;511:191-198.
38. Kompella UB, Bandi N, Ayalasomayajula SP. Subconjunctival nanoand microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci. 2003;44:1192-1201.
39. Bodker FS, Ticho BH, Feist RM, Lam TT. Intraocular dexamethasone penetration via subconjunctival or retrobulbar injections in rabbits. Ophthalmic Surg. 1993;24:453-457.
40. Yanagi Y, Tamaki Y, Obata R, et al. Subconjunctival administration of bucillamine suppresses choroidal neovascularization in rat. Invest Ophthalmol Vis Sci. 2002;43:3495-3499.
41. Lee TW, Robinson JR. Drug delivery to the posterior segment of the eye III: the effect of parallel elimination pathway on the vitreous drug level after subconjunctival injection. J Ocul Pharmacol Ther. 2004;20:55-64.
42. Alm A, Bill A. The oxygen supply to the retina. 2. Effects of high intraocular pressure and of increased arterial carbon dioxide tension on uveal and retinal blood flow in cats. A study with labelled microspheres including flow determination in brain and other tissues. Acta Physiol Scand. 1972;84:306-319.
43. Friedman E, Kopald HH, Smith TR. Retinal and choroidal blood flow determined with Krypton-85 anesthetized animals. Invest Ophthalmol. 1964;3:539-547.
44. Stefansson E, Wagner HG, Seida M. Retinal blood flow and its autoregulation measured by intraocular hydrogen clearance. Exp Eye Res. 1988;47:669-678.
45. Yu DY, Alder VA, Cringle SJ. Measurement of blood flow in rat eyes by hydrogen clearance. Am J Physiol. 1991;261:H960-H968.
46. Moseley H, Foulds WS. The movement of xenon-133 from the vitreous to the choroid. Exp Eye Res. 1982;34:169-179.
47. Moseley H, Foulds WS, Allan D, Kyle PM. Routes of clearance of radioactive water from the rabbit vitreous. Br J Ophthalmol. 1984;68:145-151.
48. Kim H, Robinson MR, Lizak MJ, et al. Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging. Invest Ophthalmol Vis Sci. 2004;45:2722-2731.
49. Park J, Bungay PM, Lutz RJ, et al. Evaluation of coupled convective-diffusive transport of drugs administered by intravitreal injection and controlled release implant. J Control Release. 2005;105:279-295.
50. Missel PJ. Finite and infinitesimal representations of the vasculature: ocular drug clearance by vascular and hydraulic effects. Ann Biomed Eng. 2002;30:1128-1139.
51. Missel PJ. Hydraulic flow and vascular clearance influences on intravitreal drug delivery. Pharm Res. 2002;19:1636-47.
52. De Schaepdrijver L, Simoens P, Lauwers H, De Geest JP. Retinal vascular patterns in domestic animals. Res Vet Sci. 1989;47:34-42.
53. Germer A, Biedermann B, Wolburg H, et al. Distribution of mitochondria within Muller cells, I. Correlation with retinal vascularization in different mammalian species. J Neurocytol. 1998;27:329-345.
54. Bill A. Movement of albumin and dextran through the sclera. Arch Ophthalmol. 1965;74:248-252.
55. Bill A. Capillary permeability to and extravascular dymanics of myoglobin, albumin and gammaglobulin in the uvea. Acta Physiol Scand. 1968;73:511-522.
56. Amrite AC, Kompella UB. Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J Pharm Pharmacol. 2005;57:1555-1563.
57. Liu H, Meagher CK, Moore CP, Phillips TE. M cells in the follicle-associated epithelium of the rabbit conjunctiva preferentially bind and translocate latex beads. Invest Ophthalmol Vis Sci. 2005;46:4217-4223.
58. Cheruvu NP, Kompella UB. Bovine and porcine transscleral solute transport: influence of lipophilicity and the choroid-Bruch's layer. Invest Ophthalmol Vis Sci. 2006;47:4513-4522.
59. Pitkanen L, Ranta VP, Moilanen H, Urtti A. Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity. Invest Ophthalmol Vis Sci. 2005;46:641-646.
60. Ghate D, Brooks W, McCarey BE, Edelhauser HF. Pharmacokinetics of intraocular drug delivery by periocular injections using ocular fluorophotometry. Invest Ophthalmol Vis Sci. 2007;48:2230-2237.